Cancer Vaccines Arrive: mRNA Breakthrough Heads for FDA Filing

Moderna and Merck just hit the jackpot: their personalized mRNA cancer vaccine, intismeran autogene, significantly reduced melanoma recurrence in a landmark Phase 3 trial of 1,137 patients. Combined with immunotherapy, it slashed the risk of cancer returning or spreading—a "pivotal moment" that sent Moderna's stock soaring 145% overnight.

"Today marks an extraordinary milestone for Moderna, for mRNA science and, most importantly, for patients with cancer." —...